financetom
Business
financetom
/
Business
/
Ecovyst Shares Fall Following Mixed Q2 Results, Guides Full-year Outlook In-Line With Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ecovyst Shares Fall Following Mixed Q2 Results, Guides Full-year Outlook In-Line With Estimates
Aug 7, 2025 9:11 AM

11:48 AM EDT, 08/07/2025 (MT Newswires) -- Ecovyst's ( ECVT ) shares fell 2.6% in recent Thursday trading after the company reported mixed Q2 results and updated its full-year outlook.

The company reported Q2 adjusted earnings of $0.12 per diluted share, the same as the year-prior quarter. That beat the estimates of analysts surveyed by FactSet for $0.10.

Revenue for the quarter ended June 30 rose to $200.1 million from $182.8 million, a year earlier. Analysts surveyed by FactSet expected $204.6 million.

The company said it now expects full-year 2025 adjusted income of $0.52 to $0.68 per diluted share, versus its previous guidance of $0.50 to $0.70 and the FactSet estimate of $0.63.

Full-year 2025 revenue is now expected to range between $795 million and $835 million, compared to its previous outlook of $785 million to $845 million. FactSet projects $797.9 million.

For Q3, the company expects adjusted EBITDA between $62 million and $72 million.

Price: 8.18, Change: -0.22, Percent Change: -2.56

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Orion Group Files for $150 Million Mixed Shelf
Orion Group Files for $150 Million Mixed Shelf
May 20, 2024
10:30 AM EDT, 05/20/2024 (MT Newswires) -- Orion Group Holdings ( ORN ) on Monday filed a registration statement covering the potential sale of up to $150 million of its securities. The filing covers the potential sale of common stock, preferred stock, warrants and rights. Net proceeds from the potential sale will be used for general corporate purposes, including working...
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise
May 20, 2024
10:30 AM EDT, 05/20/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) and Otsuka Pharmaceutical said Monday that a phase 3 trial in Japan for bempedoic acid as a potential treatment for hypercholesterolemia achieved its primary endpoint. The preliminary results showed that the percentage change from baseline in LDL cholesterol at week 12, the primary endpoint, was negative 25.25%% in...
US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea
US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea
May 20, 2024
May 20 (Reuters) - The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' ( REGN ) blockbuster eye drug Eylea, according to information on the agency's website. ...
Carlyle Group's Unit Purchases Japan KFC Holdings Stake From Mitsubishi Corporation
Carlyle Group's Unit Purchases Japan KFC Holdings Stake From Mitsubishi Corporation
May 20, 2024
10:28 AM EDT, 05/20/2024 (MT Newswires) -- Carlyle Group's ( CG ) unit, the Carlyle Fund, has acquired Mitsubishi Corporation's 35% stake of all outstanding shares of Japan KFC, Mitsubishi said Monday, following a public tender offer. Financial details of the acquisition weren't disclosed. After settlement of the sale agreed to by Mitsubishi, Japan KFC will become a wholly-owned subsidiary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved